Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,000 shares of the medical research company’s stock after buying an additional 1,500 shares during the quarter. Thermo Fisher Scientific accounts for approximately 2.7% of Sivik Global Healthcare LLC’s portfolio, making the stock its 16th largest holding. Sivik Global Healthcare LLC’s holdings in Thermo Fisher Scientific were worth $6,369,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of TMO. Linden Thomas Advisory Services LLC raised its stake in shares of Thermo Fisher Scientific by 8.8% during the 3rd quarter. Linden Thomas Advisory Services LLC now owns 1,546 shares of the medical research company’s stock worth $783,000 after buying an additional 125 shares during the last quarter. Harbor Capital Advisors Inc. raised its position in shares of Thermo Fisher Scientific by 17.7% in the third quarter. Harbor Capital Advisors Inc. now owns 1,241 shares of the medical research company’s stock valued at $628,000 after buying an additional 187 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in Thermo Fisher Scientific by 0.8% in the 3rd quarter. Commonwealth Equity Services LLC now owns 99,703 shares of the medical research company’s stock worth $50,467,000 after acquiring an additional 835 shares during the period. FAS Wealth Partners Inc. lifted its stake in shares of Thermo Fisher Scientific by 7.8% during the 3rd quarter. FAS Wealth Partners Inc. now owns 748 shares of the medical research company’s stock worth $378,000 after purchasing an additional 54 shares during the period. Finally, RMR Wealth Builders purchased a new stake in shares of Thermo Fisher Scientific in the third quarter valued at $722,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now directly owns 49,155 shares in the company, valued at $27,311,992.65. The disclosure for this sale can be found here. Insiders have sold a total of 52,277 shares of company stock valued at $29,649,264 in the last quarter. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Performance

TMO stock traded down $8.15 during trading on Tuesday, hitting $568.74. 1,514,866 shares of the company’s stock traded hands, compared to its average volume of 1,554,109. The stock has a fifty day moving average price of $574.58 and a two-hundred day moving average price of $531.67. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The stock has a market capitalization of $217.09 billion, a price-to-earnings ratio of 36.48, a price-to-earnings-growth ratio of 2.41 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. The firm had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.56 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were issued a dividend of $0.39 per share. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s payout ratio is 10.01%.

Analysts Set New Price Targets

A number of analysts have issued reports on TMO shares. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. Citigroup started coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 target price on the stock. JPMorgan Chase & Co. raised their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. Finally, Robert W. Baird decreased their price target on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a report on Thursday, April 25th. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $607.35.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.